Clinical trials: Squamous Cell Lung Carcinoma
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- KEAPSAKE (NCT04265534)
- Testing
- Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy
- Where
- 102 sites in United States
- Volunteers
- 40 people
- Sponsor
- Calithera Biosciences, Inc
Non-Squamous Cell Non-small Cell Lung Cancer
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based…
- Trial name
- CheckMate057 (NCT01673867)
- Testing
- Nivolumab, Docetaxel
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 582 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Non Small Cell Lung Cancer
Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
Primary Objective To evaluate the 3-month event-free survival of the combination of the combination of itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer.
- Trial name
- NCT00769600
- Testing
- Itraconazole, Pemetrexed
- Where
- 2 sites in United States, Singapore
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.
- Trial name
- NCT01626209
- Testing
- BKM120
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-small Cell Lung Cancer
The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab
For patients with nonsquamous NSCLC and a good performance status (PS), pemetrexed and cisplatin has been recommended for first-line NSCLC treatment.
- Trial name
- NCT02200354
- Testing
- pemetrexed with bevacizumab
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kobe City General Hospital
Lung Adenocarcinoma, Lung Large Cell Carcinoma
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual…
- Conditions
- Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT05198830
- Testing
- Carboplatin, Cisplatin, Computed Tomography
- Where
- 34 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or…
- Trial name
- SAPPHIRE (NCT03906071)
- Testing
- Nivolumab, Sitravatinib, Docetaxel
- Where
- 261 sites in United States, Belgium and 10 more
- Volunteers
- 577 people
- Sponsor
- Mirati Therapeutics Inc.
Squamous Cell Carcinoma of the Lung, Squamous Cell Carcinoma of the Head and Neck
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
This study focuses on advanced lung and head and neck SCC tumours, with adjacent normal lung tissues. Biopsies will be performed in National University Health System, Singapore (NUHS) as part of participants' standard care.
- Trial name
- NCT03938012
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than…
- Trial name
- NCT01160744
- Testing
- IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6)
- Where
- 53 sites in United States, Belgium and 4 more
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
- Trial name
- AGA TKI NSCLC (NCT07158840)
- Testing
- AK112
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Lung Cancer
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01107626
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 434 sites in United States
- Volunteers
- 1,516 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Cancer, High Grade Serous Ovarian Cancer
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to…
- Conditions
- Colorectal Cancer, High Grade Serous Ovarian Cancer, Non Small-cell Lung Cancer (Squamous Cell Variant), Urothelial Cancer
- Trial name
- NCT03096054
- Testing
- LY3143921 hydrate
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Cancer Research UK
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with…
- Trial name
- NCT07742956
- Testing
- ALK201 for injection, Ivonescimab Injection
- Volunteers
- 156 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
- Trial name
- NCT05256290
- Testing
- silevertinib (BDTX-1535) monotherapy
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Open label Enrollment in the order of confirmation of eligibility and HPV+ tumor status Prospective stratification based on 3 factors, epidermal growth factor receptor (EGFR) mutation status, performance status and first-line…
- Trial name
- NCT02531854
- Testing
- ADXS11-001, Pemetrexed
- Sponsor
- Advaxis, Inc.
Lung Cancer
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01059188
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 15 sites in Switzerland
- Volunteers
- 69 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or…
- Trial name
- NCT02657434
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 578 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.